Sarlósejtes vérszegénység: vizsgálatok itt: Egyesült Királyság
12 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisTaking peopleSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Where
- Liverpool, London, Manchester
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00 - 4. fázisCsak meghívásosA Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
- Where
- Manchester
- Életkor
- 18 év and over
- People
- 55 worldwide
- Run by
- Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00 - 3. fázisTaking peopleThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Where
- London, Manchester
- Életkor
- 10 év to 65 év
- People
- 192 worldwide
- Run by
- Sanofi
See details and how to joinNCT06975865 - 2. fázisTaking peopleSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- Where
- Liverpool, London
- Életkor
- 12 év and over
- People
- 70 worldwide
- Run by
- CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00 - 2. fázisTaking peopleA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
- Where
- London, Manchester
- Életkor
- 6 hónap to 18 év
- People
- 95 worldwide
- Run by
- Forma Therapeutics, Inc.
See details and how to joinNCT06198712 · EU 2024-519881-32-00 - 3. fázisTaking peopleA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Where
- London, Manchester, Sheffield
- Életkor
- 2 év and over
- People
- 480 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06609226 · EU 2024-510805-27-00 - 3. fázisTaking peopleA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Where
- Cambridge, London
- Életkor
- 12 év and over
- People
- 510 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00 - 2/3. fázisTaking peopleA Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- Where
- Bristol, London
- Életkor
- 12 év to 64 év
- People
- 389 worldwide
- Run by
- Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00 - 1/2. fázisTaking peopleA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Where
- East Sussex, Leeds, London
- Életkor
- 18 év and over
- People
- 224 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06481306 · EU 2023-510283-12-00 - 3. fázisCsak meghívásosA Long-term Follow-up Study in Participants Who Received CTX001
- Where
- London
- Életkor
- 2 év to 64 év
- People
- 160 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00 - No phaseTaking peoplePASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]
- Where
- Basildon, Cardiff, London, Manchester, Oxford
- Életkor
- 9 hónap to 23 hónap
- People
- 180 worldwide
- Run by
- Nova Laboratories Limited
See details and how to joinNCT06923111 - 3. fázisTaking peopleRElated Haplo-DonoR Haematopoietic stEm Cell Transplantation for Adults With Severe Sickle Cell Disease
- Where
- London
- Életkor
- 18 év and over
- People
- 120
- Run by
- King's College Hospital NHS Trust
See details and how to joinNCT05392894